MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS

Shahram Majidi, Marie Luby, John K. Lynch, Amie W. Hsia, Richard T. Benson, Chandni P. Kalaria, Zurab Nadareishvili, Lawrence L. Latour, Richard Leigh

Research output: Contribution to journalArticlepeer-review

Abstract

ObjectiveTreatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit. We studied the safety and efficacy of thrombolysis in a population of patients with acute stroke presenting with low NIH Stroke Scale (NIHSS) scores screened using MRI.MethodsThe NIH Natural History of Stroke database was reviewed from January 2006 to December 2016 to identify all patients with an initial NIHSS score =5 who received thrombolysis within 4.5 hours of symptom onset after being screened with MRI. The 24-hour postthrombolysis MRIs were reviewed for hemorrhagic transformation. Primary outcomes were symptomatic intracranial hemorrhage (sICH) and favorable 90-day outcome modified Rankin Scale score 0-1. Subgroup analysis was performed on patients who would have been eligible for the PRISMS trial, which enrolled patients with a nondisabling neurologic deficit.ResultsA total of 121 patients were included in the study with a median age of 65 and an NIHSS score of 3; 63% were women. The rate of any hemorrhagic transformation was 13%, with 11% of them being limited to petechial hemorrhage. The rate of sICH was <1%. Sixty-six patients had 90-day outcome data; of those, 74% had a favorable outcome. For the subgroup of 81 PRISMS-eligible patients, none experienced sICH. Fifty of these patients had 90-day outcome data; of these, 84% had a favorable outcome.ConclusionsThrombolytic therapy was safe in our patients with stroke with minor deficits who were initially evaluated by MRI. Future studies of this population may benefit from MRI selection.Classification of evidenceThis study provides Class IV evidence that for patients with acute ischemic stroke and NIHSS =5 screened with MRI, IV tissue plasminogen activator is safe.

Original languageEnglish (US)
Pages (from-to)E1507-E1513
JournalNeurology
Volume93
Issue number16
DOIs
StatePublished - Oct 15 2019
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS'. Together they form a unique fingerprint.

Cite this